Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 19268798 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS | July 2025 | September 2025 | Allow | 2 | 0 | 0 | No | No |
| 19224580 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 19218915 | APPLICATION OF GENIPIN BETA-METHYL DERIVATIVE GEN-17 IN PREPARATION OF DRUG FOR PREVENTION AND TREATMENT OF ACUTE SEVERE PNEUMONIA | May 2025 | September 2025 | Allow | 3 | 1 | 0 | No | No |
| 19210905 | METHOD FOR CARBON DIOXIDE FIXATION USING A PALLADIUM-DOPED NITROGEN-RICH ORGANIC FRAMEWORK CATALYST | May 2025 | August 2025 | Allow | 3 | 1 | 0 | No | No |
| 18988636 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | December 2024 | May 2025 | Allow | 5 | 1 | 0 | No | No |
| 18978995 | PROCESS FOR MAKING AN ISOXAZOLINE COMPOUND AND INTERMEDIATE THEREOF | December 2024 | April 2025 | Allow | 4 | 1 | 0 | Yes | No |
| 18925543 | 2,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA 3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2024 | June 2025 | Abandon | 8 | 1 | 0 | No | No |
| 18895254 | METHOD FOR PREPARING 5-HYDROXYMETHYLFURFURAL | September 2024 | February 2025 | Allow | 5 | 1 | 0 | No | No |
| 18824811 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | September 2024 | November 2024 | Allow | 2 | 1 | 0 | Yes | No |
| 18795384 | METHODS FOR TREATING CANCER | August 2024 | January 2025 | Allow | 5 | 1 | 0 | Yes | No |
| 18778902 | METHOD FOR CONTINUOUSLY SYNTHESIZING 5-HYDROXYMETHYLFURFURAL BY USING MICRO-CHANNEL REACTOR | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18770589 | METHOD FOR SYNTHESIZING 1,3,2-DIOXATHIOLANE 2,2-DIOXIDE BY IN-SITU CATALYTIC OXIDATION | July 2024 | December 2024 | Allow | 5 | 1 | 0 | No | No |
| 18747540 | 3-PYRROLIDINE-INDOLE DERIVATIVES AS SEROTONERGIC PSYCHEDELIC AGENTS FOR THE TREATMENT OF CNS DISORDERS | June 2024 | July 2025 | Allow | 13 | 2 | 0 | No | No |
| 18742346 | METHOD FOR THE PREPARATION OF (4S)-4-(4-CYANO-2-METHOXYPHENYL)-5-ETHOXY-2,8-DIMETHYL-1,4-DIHYDRO-1-6-NAPHTHYRIDINE-3-CARBOX-AMIDE BY RACEMATE SEPARATION BY MEANS OF DIASTEREOMERIC TARTARIC ACID ESTERS | June 2024 | April 2025 | Allow | 10 | 1 | 0 | No | No |
| 18655452 | PROCESS FOR PREPARING N-(5-(3-(7-(3-FLUOROPHENYL)-3H-IMIDAZO[4,5-C]PYRIDIN-2-YL)-1H-INDAZOL-5-YL)PYRIDIN-3-YL)-3-METHYLBUTANAMIDE | May 2024 | August 2025 | Allow | 16 | 1 | 0 | Yes | No |
| 18637793 | COMPOUNDS FOR THE REDUCING LIPOTOXIC DAMAGE | April 2024 | February 2025 | Allow | 10 | 1 | 0 | No | No |
| 18635657 | ACETYLSALICYLIC ACID DERIVATIVE AND APPLICATION THEREOF | April 2024 | August 2025 | Allow | 16 | 2 | 0 | Yes | No |
| 18633272 | TARGETED DEGRADATION OF VAV1 | April 2024 | August 2024 | Allow | 4 | 1 | 0 | No | No |
| 18699960 | COUPLED UREA MELAMINE PLANT | April 2024 | February 2025 | Allow | 11 | 1 | 1 | No | No |
| 18586669 | METHOD FOR TREATING OBESITY, DIABETES, CARDIOVASCULAR AND KIDNEY DISEASES BY REGULATING GPR30/GPER ACTIVITY | February 2024 | April 2025 | Abandon | 13 | 1 | 0 | No | No |
| 18442393 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | February 2024 | December 2024 | Allow | 10 | 1 | 0 | No | No |
| 18440652 | METHODS OF ADMINISTERING ANTI-FIBROTIC THERAPY | February 2024 | November 2024 | Allow | 9 | 1 | 0 | No | No |
| 18437227 | 5-(2,4,5-TRIS(4-CHLOROPHENYL)-1H-IMIDAZOL-1-YL)PENTANOIC ACID AS AN ANTIMICROBIAL COMPOUND | February 2024 | July 2024 | Allow | 5 | 1 | 0 | No | No |
| 18429126 | [3-(4-METHOXYPHENYL)-1,2,4-OXADIAZOL-5-YL]METHANOL AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | January 2024 | October 2024 | Allow | 8 | 2 | 0 | No | No |
| 18421914 | METHODS FOR TREATING SUBJECTS WITH PRADER-WILLI SYNDROME OR SMITH-MAGENIS SYNDROME | January 2024 | July 2024 | Allow | 6 | 1 | 0 | No | No |
| 18412805 | ASCORBIC ACID AND QUINONE COMPOUNDS IN COMBINATION WITH AN ANTIPARASITIC AGENT FOR TREATING A PARASITIC DISEASE | January 2024 | January 2025 | Allow | 12 | 1 | 0 | No | No |
| 18392203 | SELECTIVE LIGANDS FOR MODULATION OF GIRK CHANNELS | December 2023 | March 2025 | Allow | 14 | 1 | 0 | No | No |
| 18391421 | PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF | December 2023 | December 2024 | Allow | 12 | 1 | 0 | No | No |
| 18535256 | OXYSTEROLS AND METHODS OF USE THEREOF | December 2023 | May 2025 | Allow | 17 | 1 | 0 | No | No |
| 18534078 | 7-(4-FLUOROBENZYLIDENE)-4-(4-FLUOROPHENYL)-2-METHOXY-6,7-DIHYDRO-5H-CYCLOPENTA[B]PYRIDINE-3-CARBONITRILE AS AN ANTIMICROBIAL COMPOUND | December 2023 | March 2024 | Allow | 3 | 1 | 0 | No | No |
| 18533625 | 3-CYANO-2-ETHOXY-9-(2-NITROBENZYLIDENE)-4-(2-NITROPHENYL)-6,7,8,9-TETRAHYDRO-5H-CYCLOHEPTA[B]PYRIDINE AS AN ANTIMICROBIAL COMPOUND | December 2023 | April 2024 | Allow | 4 | 1 | 0 | No | No |
| 18528910 | METHOD OF PREPARING AN EXTRACT OF CHAYOTE | December 2023 | September 2024 | Abandon | 9 | 1 | 0 | No | No |
| 18516604 | COMPOSITIONS OF TROFINETIDE | November 2023 | January 2025 | Allow | 14 | 1 | 0 | No | No |
| 18509967 | METHODS FOR TREATING CANCER | November 2023 | May 2024 | Allow | 6 | 1 | 0 | Yes | No |
| 18386684 | 9-(2-HYDROXYQUINOLINE-3-YL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10-HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18386557 | 2-[9-(2-HYDROXYPYRIDIN-3-YL)-1,8-DIOXO-1,2,3,4,5,-6,7,8,9,10-DECAHYDROACRIDIN-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUND | November 2023 | February 2024 | Allow | 3 | 1 | 0 | No | No |
| 18386465 | ETHYL 2-[9-(6-CHLORO-2-HYDROXYQUINOLIN-3-YL)-3,6-DIPHENYL-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18558454 | ADENOSINE A3 RECEPTOR ANTAGONISTS FOR TREATING AGING SKIN AND WOUNDS | November 2023 | December 2024 | Allow | 13 | 1 | 1 | No | No |
| 18385628 | 9-(2-HYDROXYPYRIDIN-3-YL)-10-(2-HYDROXYETHYL)-3,6-DIPHENYL-3,4,6,7,9,10-HEXAHYDROACRIDINE1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18494818 | COMPOUNDS, COMPOSITIONS, METHODS OF USING, AND METHODS FOR PREPARING COMPOUNDS | October 2023 | April 2025 | Allow | 17 | 1 | 0 | Yes | No |
| 18491538 | ISOQUINOLINE COMPOUNDS AND THEIR USE IN TREATING AhR IMBALANCE | October 2023 | November 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18491598 | SULFOPEROXYCARBOXYLIC ACIDS, THEIR PREPARATION AND METHODS OF USE AS BLEACHING AND ANTIMICROBIAL AGENTS | October 2023 | September 2024 | Allow | 11 | 1 | 0 | Yes | No |
| 18488871 | SUBSTITUTED PYRIDO[3,4-B]INDOLES FOR THE TREATMENT OF CARTILAGE DISORDERS | October 2023 | November 2024 | Allow | 13 | 1 | 0 | No | No |
| 18381085 | 12-BROMO-2,16-DIOXAPENTACYCLO[7.7.5.01,21.03,8.010,15]HENICOSA3(8),10,12,14-TETRAENE-7,20-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18486783 | NOVEL USE OF PYRROLOPYRIDINE DERIVATIVES FOR PREVENTING OR TREATING INFLAMMATORY DISEASES | October 2023 | November 2024 | Allow | 13 | 1 | 0 | No | No |
| 18380018 | N'-({[(5-PHENYL-1,3,4-OXADIAZOL-2-YL)SULFANYL]ACETYL}OXY)BENZENECARBOXIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18378901 | TREATMENT FOR PARKINSON'S DISEASE | October 2023 | December 2024 | Allow | 14 | 1 | 1 | Yes | No |
| 18379115 | N'-(2-(5-(4-CHLOROPHENYL)-1,3,4-OXADIAZOL-2-YLTHIO)ACETOXY)BENZIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 1 | 0 | No | No |
| 18376526 | INHIBITORS OF COMPLEMENT FACTORS AND USES THEREOF | October 2023 | October 2025 | Allow | 25 | 1 | 0 | No | No |
| 18371619 | Topical Composition Containing Antioxidants | September 2023 | September 2024 | Allow | 12 | 1 | 0 | Yes | No |
| 18471594 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | September 2023 | January 2025 | Allow | 16 | 1 | 0 | No | No |
| 18370983 | 1-CYCLOPROPYL-6-FLUORO-4-OXO-7-(4-((5-OXO-2-PHENYL-4-(QUINOLIN-2-YLMETHYLENE)-4,5-DIHYDRO-1H-IMIDAZOL-1-YL)METHYL)PIPERAZIN-1-YL)-1,4-DIHYDROQUINOLINE-3-CARBOXYLIC ACID AS AN ANTI-INFLAMMATORY AND ANTICANCER COMPOUND | September 2023 | February 2024 | Allow | 5 | 1 | 0 | No | No |
| 18244913 | COMPOUNDS FOR TREATING TNBC | September 2023 | January 2025 | Allow | 16 | 2 | 0 | No | No |
| 18243991 | FOLATE SALTS | September 2023 | November 2024 | Allow | 14 | 2 | 0 | No | No |
| 18462899 | ERGOLINE ANALOGUES | September 2023 | July 2024 | Allow | 10 | 1 | 0 | No | No |
| 18460012 | CANNABIS COMPOSITION | September 2023 | October 2024 | Allow | 14 | 1 | 0 | No | No |
| 18279567 | PROCESS FOR PREPARING N,N'-BIS(2,2,6,6-TETRAMETHYLPIPERIDIN-4-YL)HEXANE-1,6-DIAMINE | August 2023 | February 2026 | Allow | 30 | 1 | 0 | Yes | No |
| 18239528 | 1,3-BENZOTHIAZOL-2-YL-N'-(BENZOYLOXY)ETHANIMIDAMIDE AS AN ANTITUMOR AND ANTIMICROBIAL COMPOUND | August 2023 | January 2024 | Allow | 5 | 1 | 0 | No | No |
| 18236795 | TOXIC ALDEHYDE RELATED DISEASES AND TREATMENT | August 2023 | June 2024 | Allow | 10 | 1 | 0 | No | No |
| 18451465 | Pharmaceutical Compositions Comprising Heterocycle Fused Gamma Carboline Prodrugs | August 2023 | August 2024 | Allow | 12 | 1 | 0 | No | No |
| 18450586 | METHODS FOR TREATING CANCER | August 2023 | November 2023 | Allow | 3 | 0 | 0 | No | No |
| 18450902 | CATALYST SUPPORTS - COMPOSITION AND PROCESS OF MANUFACTURE | August 2023 | November 2024 | Allow | 15 | 1 | 0 | No | No |
| 18264435 | INDOLE ALKALOID AND PREPARATION METHOD AND USE THEREOF | August 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18263796 | PROCESS FOR THE EPOXIDATION OF PROPENE | August 2023 | November 2025 | Allow | 28 | 0 | 0 | Yes | No |
| 18363006 | METHODS FOR PREVENTING OR TREATING H. PYLORI INFECTION | August 2023 | April 2024 | Allow | 8 | 2 | 0 | No | No |
| 18228238 | NOVEL NANO-SIZED 4-BROMO-2-[(9H-PURIN-6-YLIMINO)-METHYL]-PHENOL IMINE PD(II) COMPLEX FOR SUPERIOR PHARMACEUTICAL APPLICATIONS | July 2023 | October 2023 | Allow | 3 | 1 | 0 | No | No |
| 18273843 | Compounds for Disease Treatment | July 2023 | February 2026 | Allow | 31 | 1 | 0 | No | No |
| 18218438 | RECTAL GEL WITH DATE PALM PHENOLICS AND VANILLIC ACID | July 2023 | October 2023 | Allow | 3 | 1 | 0 | No | No |
| 18270743 | INDOLE COMPOUNDS, AND PREPARATION METHODS, AND USES THEREOF | July 2023 | January 2026 | Allow | 31 | 1 | 0 | No | No |
| 18269830 | CROMOLYN DERIVATIVES AND USES THEREOF | June 2023 | March 2026 | Allow | 33 | 1 | 0 | No | No |
| 18334668 | NEAR INFRARED PHOTOCATALYST BASED ON TIO2-COATED GOLD NANOPARTICLES | June 2023 | June 2024 | Allow | 12 | 0 | 1 | Yes | No |
| 18256596 | METHODS TO SYNTHESIZE FLAVONOID DIMERS AND OLIGOMERS AND THE USE THEREOF | June 2023 | March 2026 | Abandon | 33 | 1 | 0 | No | No |
| 18326732 | CRYSTALLINE HYDRATE OF A JAK INHIBITOR COMPOUND | May 2023 | June 2024 | Allow | 13 | 1 | 0 | No | No |
| 18039236 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT AND PROPHYLAXIS OF MICROBIAL INFECTIOUS DISEASES AND ASSOCIATED INFLAMMATORY DISORDERS AND FOR THE TREATMENT AND PROPHYLAXIS OF AGING AND ASSOCIATED DISEASES | May 2023 | February 2026 | Allow | 33 | 2 | 0 | No | No |
| 18254620 | PROCESS FOR THE PRODUCTION OF ETHYLENE OXIDE | May 2023 | December 2025 | Allow | 31 | 1 | 0 | Yes | No |
| 18254211 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING WOUND OR SCAR, COMPRISING BENZBROMARONE | May 2023 | February 2024 | Allow | 8 | 1 | 0 | No | No |
| 18322290 | METHOD OF TREATMENT | May 2023 | September 2024 | Abandon | 15 | 1 | 0 | No | No |
| 18322167 | SOLID FORM OF (-)-AMBROX FORMED BY A BIOCONVERSION OF HOMOFARNESOL IN THE PRESENCE OF A BIOCATALYST | May 2023 | May 2024 | Allow | 11 | 1 | 0 | No | No |
| 18038317 | CANNABINOID DERIVATIVES AND THEIR USE THE TREATMENT OF INFLAMMATION AND/OR PAIN AND/OR OBESITY | May 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18320060 | CRYSTALLINE FORMS OF IRAK DEGRADERS | May 2023 | March 2026 | Abandon | 33 | 1 | 0 | No | No |
| 18035627 | COMPOSITION FOR PREVENTING OR TREATING TNF-alpha-RELATED DISEASE, COMPRISING HYDROFLUMETHIAZIDE AS ACTIVE INGREDIENT | May 2023 | December 2025 | Allow | 32 | 1 | 0 | No | No |
| 18251646 | METHOD FOR PREPARING CRYSTALLINE PARTICLES OF 1-(3-CYANO-1-ISOPROPYL-INDOLE-5-YL)PYRAZOLE-4-CARBOXYLIC ACID, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | May 2023 | March 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18142973 | 3-(4-((4-(MORPHOLINOMETHYL-BENZYL)OXY)-1 -OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS | May 2023 | July 2024 | Abandon | 14 | 1 | 0 | No | No |
| 18311266 | N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS | May 2023 | February 2025 | Allow | 21 | 1 | 0 | Yes | No |
| 18297285 | CALMODULIN INHIBITORS FOR THE TREATMENT OF RIBOSOMAL DISORDERS AND RIBOSOMOPATHIES | April 2023 | December 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 18131695 | TRANSTHYRETIN TETRAMER STABILIZING AGENT, AND PREVENTING AGENT OR PROGRESSION SUPPRESSING AGENT FOR TRANSTHYRETIN AMYLOIDOSIS | April 2023 | January 2026 | Allow | 34 | 1 | 0 | Yes | No |
| 18124071 | PYRROLOPYRROLE COMPOSITIONS AS PYRUVATE KINASE (PKR) ACTIVATORS | March 2023 | April 2024 | Allow | 13 | 1 | 0 | No | No |
| 18184364 | METHODS OF USING 4(1H)-QUINOLONE DERIVATIVES | March 2023 | July 2024 | Allow | 16 | 1 | 0 | Yes | No |
| 18120033 | N-N-DIMETHYLTRYPTAMINE (DMT) AND DMT ANALOG COMPOSITIONS, METHODS OF MAKING, AND METHODS OF USE THEREOF | March 2023 | April 2024 | Allow | 13 | 1 | 0 | Yes | No |
| 18178062 | COMPOUNDS FOR THE REDUCING LIPOTOXIC DAMAGE | March 2023 | January 2024 | Allow | 10 | 1 | 0 | No | No |
| 18176048 | BETA-LACTAMASE INHIBITORS AND USES THEREOF | February 2023 | August 2024 | Abandon | 18 | 2 | 0 | No | No |
| 18113721 | RECTAL GEL WITH DATE PALM PHENOLICS AND VANILLIC ACID | February 2023 | August 2023 | Allow | 6 | 1 | 1 | No | No |
| 18022767 | METHOD FOR PRODUCING ETHYLENE OXIDE | February 2023 | December 2025 | Allow | 34 | 1 | 0 | No | No |
| 18169807 | PROCESSES FOR THE PREPARATION OF 2,5-FURANDICARBOXYLIC ACID AND INTERMEDIATES AND DERIVATIVES THEREOF | February 2023 | September 2023 | Allow | 7 | 1 | 0 | No | No |
| 18041394 | PURIFICATION OF 2,5-FURANDICARBOXYLIC ACID, DIMETHYL ESTER AND OTHER ESTERIFIED PRODUCTS | February 2023 | January 2026 | Allow | 35 | 1 | 0 | No | No |
| 18020120 | COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING INFLAMMATORY DISEASE CONTAINING ISOOKANIN OR SALT THEREOF AS ACTIVE INGREDIENT | February 2023 | November 2025 | Allow | 33 | 1 | 0 | Yes | No |
| 18005001 | METHOD FOR PREPARING PROPYLENE OXIDE BY MEANS OF DIRECT EPOXIDATION OF PROPYLENE | January 2023 | December 2025 | Allow | 35 | 1 | 0 | No | No |
| 18004806 | GLUCOCORTICOID-SPARING AGENT | January 2023 | January 2026 | Allow | 37 | 1 | 0 | No | No |
| 18013688 | INDOLE DERIVATIVE AND APPLICATION THEREOF | December 2022 | October 2025 | Allow | 34 | 1 | 0 | No | No |
| 18085622 | MOLECULE HAVING PESTICIDAL UTILITY AND PROCESSES RELATED THERETO | December 2022 | February 2024 | Abandon | 14 | 2 | 0 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner OH, TAYLOR V.
With a 53.8% reversal rate, the PTAB has reversed the examiner's rejections more often than affirming them. This reversal rate is in the top 25% across the USPTO, indicating that appeals are more successful here than in most other areas.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 39.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is above the USPTO average, suggesting that filing an appeal can be an effective strategy for prompting reconsideration.
✓ Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.
✓ Filing a Notice of Appeal is strategically valuable. The act of filing often prompts favorable reconsideration during the mandatory appeal conference.
Examiner OH, TAYLOR V works in Art Unit 1625 and has examined 1,532 patent applications in our dataset. With an allowance rate of 77.8%, this examiner has a below-average tendency to allow applications. Applications typically reach final disposition in approximately 24 months.
Examiner OH, TAYLOR V's allowance rate of 77.8% places them in the 45% percentile among all USPTO examiners. This examiner has a below-average tendency to allow applications.
On average, applications examined by OH, TAYLOR V receive 1.89 office actions before reaching final disposition. This places the examiner in the 45% percentile for office actions issued. This examiner issues fewer office actions than average, which may indicate efficient prosecution or a more lenient examination style.
The median time to disposition (half-life) for applications examined by OH, TAYLOR V is 24 months. This places the examiner in the 81% percentile for prosecution speed. Applications move through prosecution relatively quickly with this examiner.
Conducting an examiner interview provides a +12.7% benefit to allowance rate for applications examined by OH, TAYLOR V. This interview benefit is in the 49% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 35.1% of applications are subsequently allowed. This success rate is in the 78% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 69.9% of cases where such amendments are filed. This entry rate is in the 92% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.
When applicants request a pre-appeal conference (PAC) with this examiner, 25.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 29% percentile among all examiners. Note: Pre-appeal conferences show below-average success with this examiner. Consider whether your arguments are strong enough to warrant a PAC request.
This examiner withdraws rejections or reopens prosecution in 87.0% of appeals filed. This is in the 80% percentile among all examiners. Of these withdrawals, 62.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 58.9% are granted (fully or in part). This grant rate is in the 62% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 8.1% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.6% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.